BRCA1 and cancer: With the advancement of cancer genomic study, recent advanced research in poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy for advanced epithelial serous ovarian carcinomas patients with BRCA1/2 mutation after finishing postoperative adjuvant first-line chemotherapy significantly prolonged the progress-free survival but the overall survival impact still needs to be investigated [24].